HK1245133A1 - 用伊立替康脂质体治疗乳腺癌 - Google Patents

用伊立替康脂质体治疗乳腺癌 Download PDF

Info

Publication number
HK1245133A1
HK1245133A1 HK18104815.5A HK18104815A HK1245133A1 HK 1245133 A1 HK1245133 A1 HK 1245133A1 HK 18104815 A HK18104815 A HK 18104815A HK 1245133 A1 HK1245133 A1 HK 1245133A1
Authority
HK
Hong Kong
Prior art keywords
breast cancer
treatment
liposomal irinotecan
positive
positive breast
Prior art date
Application number
HK18104815.5A
Other languages
English (en)
Chinese (zh)
Inventor
Eliel Bayever
Jonathan Basil Fitzgerald
Jaeyeon Kim
Stephan Klinz
Original Assignee
Ipsen Biopharm Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd. filed Critical Ipsen Biopharm Ltd.
Publication of HK1245133A1 publication Critical patent/HK1245133A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18104815.5A 2014-12-09 2015-12-08 用伊立替康脂质体治疗乳腺癌 HK1245133A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462089685P 2014-12-09 2014-12-09
US62/089,685 2014-12-09
PCT/US2015/064491 WO2016094402A1 (en) 2014-12-09 2015-12-08 Treatment of breast cancer with liposomal irinotecan

Publications (1)

Publication Number Publication Date
HK1245133A1 true HK1245133A1 (zh) 2018-08-24

Family

ID=54979964

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18104815.5A HK1245133A1 (zh) 2014-12-09 2015-12-08 用伊立替康脂质体治疗乳腺癌

Country Status (6)

Country Link
US (2) US20160346272A1 (enExample)
EP (1) EP3229802A1 (enExample)
JP (3) JP7113619B2 (enExample)
AU (1) AU2015360761B2 (enExample)
HK (1) HK1245133A1 (enExample)
WO (1) WO2016094402A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
HK1257216A1 (zh) 2015-08-20 2019-10-18 益普生生物制药有限公司 使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法
BR112018002941B1 (pt) * 2015-08-21 2023-12-05 Ipsen Biopharm Ltd Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas
BR112018006922B1 (pt) 2015-10-16 2023-11-21 Ipsen Biopharm Ltd Composições de irinotecano lipossômico estabilizado para armazenamento
CN110402163A (zh) 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
KR20210040997A (ko) * 2018-08-05 2021-04-14 다 볼떼라 항암제 효능의 개선 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI283575B (en) * 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
RU2424792C2 (ru) 2004-05-03 2011-07-27 Хермес Байесайенсиз, Инк. Липосомы, используемые для доставки лекарственных средств
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
WO2007109184A2 (en) * 2006-03-16 2007-09-27 Bionumerik Pharmaceuticals, Inc. Anti-cancer activity augmentation compounds and formulations and methods of use thereof
EP2595618A1 (en) * 2010-07-19 2013-05-29 BiPar Sciences, Inc. Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US20140120157A1 (en) * 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
WO2014113167A1 (en) * 2012-12-14 2014-07-24 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents
HK1257216A1 (zh) * 2015-08-20 2019-10-18 益普生生物制药有限公司 使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法
BR112018002941B1 (pt) * 2015-08-21 2023-12-05 Ipsen Biopharm Ltd Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas
BR112018006922B1 (pt) * 2015-10-16 2023-11-21 Ipsen Biopharm Ltd Composições de irinotecano lipossômico estabilizado para armazenamento

Also Published As

Publication number Publication date
US20160346272A1 (en) 2016-12-01
JP2022079545A (ja) 2022-05-26
EP3229802A1 (en) 2017-10-18
AU2015360761B2 (en) 2021-05-20
WO2016094402A1 (en) 2016-06-16
AU2015360761A1 (en) 2017-06-15
JP2017537124A (ja) 2017-12-14
JP7113619B2 (ja) 2022-08-05
JP2020073601A (ja) 2020-05-14
US20200360367A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
HK1245133A1 (zh) 用伊立替康脂质体治疗乳腺癌
WO2015082990A8 (en) Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
MY186977A (en) Tetrasubstituted alkene compounds and their use
EP3222278A4 (en) Use of azelnidipine in preparing medicinal composition for treating cancers
WO2014149477A8 (en) Methods for achieving therapeutically effective doses of anti-cd47 agents
IL239981B1 (en) Combined therapy involving antibodies against claudin 18.2 for the treatment of cancer
EP3337482A4 (en) TRANSDERMAL FORMULATIONS FOR THE DISTRIBUTION OF BERBERIN COMPOUNDS AND THEIR USE IN THE TREATMENT OF BERBER INDEPENDENT ILLNESSES AND DISORDERS
CA2908957C (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
HUE059448T2 (hu) Liposzómás készítmény, rák kezelésében való alkalmazásra
EP3079680A4 (en) Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders
ZA201700922B (en) Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anti-cancer ingredient, pharmaceutical composition, medicinal preparation, method for treating prostate cancer
EP3033150A4 (en) Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
EP3295949A4 (en) Topical drug for treating breast cancer and preparation method thereof
EP3100744A4 (en) Composition for accelerating penetration through skin, preparation for transdermal administration, and skin patch preparation
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
EP3190887A4 (en) Methods for treating and preventing ocular diseases, disorders, and conditions with melanin and melanin analogs, precursors, and derivatives
ZA201802399B (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
IL246065A0 (en) Valiprib in combination with carboplatin for the treatment of triple negative breast cancer
EP3100743A4 (en) Composition for accelerating penetration through skin, preparation for transdermal administration, and skin patch preparation
HK1206275A1 (en) Arry-520 for use in treating cancer in a patient with low aag
HK40008065A (en) Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (immu-132)
HK40005217A (en) Triple negative breast cancer treatment method
HK1261631B (en) Combination for the effective treatment of metastatic cancer in patients